Cullinan Therapeutics details new biomarker approach for immune reset in autoimmune disease research

Cullinan Therapeutics details new biomarker approach for immune reset in autoimmune disease research
Cullinan unveils immune reset strategy

Cullinan Therapeutics has introduced a new biomarker-driven approach aimed at elucidating immune reset mechanisms in autoimmune diseases, according to a MassBio article.

Chief Scientific Officer Jennifer Michaelson, PhD, and Vice President of Translational Research Irina Shapiro, PhD, presented the strategy, emphasizing how it could advance the understanding and treatment of autoimmune conditions. The company’s latest efforts reflect ongoing innovation in translational research methods focused on improving clinical outcomes for patients with immune disorders.

Cullinan Therapeutics previously pursued T cell engager therapies targeting B cells to address the root causes of autoimmune diseases, as detailed in earlier research initiatives. The company also released initial clinical data for its investigational T cell engager CLN-978 in systemic lupus erythematosus and rheumatoid arthritis at EULAR2026, according to presentations on its clinical programs. These efforts reflect Cullinan's ongoing focus on innovative approaches in the autoimmune space.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.
Weekly Top Bonuses
up to $2,500
deposit bonus for all clients
CLAIM BONUS
Your capital is at risk.